Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies
NCT04349436Phase 2Active, not recruiting
- Sponsor
- Replimune Group, Inc.
- Start
- May 2020
- Primary completion
- Jul 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vusolimogene oderparepvec in cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), Merkel cell carcinoma (MCC) and 1 more, sponsored by Replimune Group, Inc. Primary endpoints: Objective Response Rate at 36 months and Safety and Tolerability at 36 months. Started May 2020; status: active, not recruiting.
02
Drugs
vusolimogene oderparepvec
03
Conditions
cutaneous squamous cell carcinoma (cSCC)basal cell carcinoma (BCC)Merkel cell carcinoma (MCC)melanoma
Beyond the preview
Go deeper on NCT04349436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349436.